Status:
UNKNOWN
iLIVE Medication Study
Lead Sponsor:
Prof. dr. Stefan Sleijfer
Collaborating Sponsors:
Lund University
Landspitali University Hospital
Conditions:
Palliative Care
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The iLIVE medication study is a before-after study where medication optimisation of patients with an estimated life expectancy of six months is investigated. The investigators will include 400 patient...
Detailed Description
Rationale: Patients in the last phase of life often use many medications until shortly before they die. This is partly inevitable, because these patients often experience multiple distressing symptoms...
Eligibility Criteria
Inclusion
- Inclusion criteria for patients:
- Patient is 18 years or over and provides informed consent to participate.
- The patient is aware that recovering from his/her disease is unlikely, as assessed by the attending physician.
- The patient agrees to participate in the iLIVE cohort study.
- The attending physician would not be surprised if the patient would die within 6 months ('Surprise question').
- If the physician is uncertain about the surprise question, the patient is eligible if presenting with at least one SPICT indicator. The SPICT™ is a tool to help professionals identify people with general indicators of poor or deteriorating health and clinical signs of life-limiting conditions for assessment and care planning, based on general or disease-specific indicators.
- Inclusion criteria for relative/informal caregiver of included patients:
- Relatives of included patients are asked to participate if they are: 18 years or over and provide informed consent to participate; aware that it is unlikely that the patient will recover from his/her disease; and capable of filling in a questionnaire in the country's main language or in English.
- Exclusion Criteria:
- The patient is incapable of filling in a questionnaire in the country's main language or in English (patients may be supported by relatives when filling in the questionnaire).
- The attending physician makes the decision that the patient should not be included in the study due to e.g. illness burden, fast deterioration or imminent death, lack of trusting relationship with the physician.
Exclusion
Key Trial Info
Start Date :
January 15 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 15 2024
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT04717882
Start Date
January 15 2021
End Date
January 15 2024
Last Update
January 22 2021
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Erasmus Medical Center
Rotterdam, Netherlands
2
Skåne University Hospital
Lund, Sweden
3
Bern University Hospital
Bern, Switzerland